Yosef Yarden,
Moshe Elkabets
Springer International Publishing
e druk, 2019
9783030098179
Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
Specificaties
Paperback, blz.
|
Engels
Springer International Publishing |
e druk, 2019
ISBN13: 9783030098179
Rubricering
Onderdeel van serie
Resistance to Targeted Anti-Cancer Therapeutics
Verwachte levertijd ongeveer 9 werkdagen
Samenvatting
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
Specificaties
ISBN13:9783030098179
Taal:Engels
Bindwijze:paperback
Uitgever:Springer International Publishing
Inhoudsopgave
Resistance of colorectal tumors to anti-EGFR antibodies.- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK.- Mechanisms of action and resistance of trastuzumab in breast cancer.- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis.- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge.- Mechanisms of resistance to PI3K and AKT inhibitors.- Sensitivity and resistance to BH3 mimetics in cancer therapy.- Resistance mechanisms to cyclin-dependent kinase inhibitors.- Resistance to inhibitors of angiogenesis.<br/><p></p>
